SCHEMBL22084756

SCHEMBL22084756

OC1CN(c2ncc(-c3cn(-c4cccnc4)c4ncnc(Cl)c34)cn2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 5/20 0.52
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ PI4KA P42356 1/20 0.39
▸ PI4K2B Q8TCG2 1/20 0.39
▸ PI4K2A Q9BTU6 1/20 0.39
▸ PI4KB Q9UBF8 1/20 0.39
▸ LMNA P02545 4/20 0.39
▸ TP53 P04637 3/20 0.38
▸ HTT P42858 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ BTK Q06187 1/20 0.37
▸ EGFR P00533 3/20 0.37
▸ ABL1 P00519 2/20 0.37
▸ KDR P35968 2/20 0.37
▸ ABL2 P42684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22084755 0.91 SRC (0.65) SRCCA12CA1CA2CA9
SCHEMBL22086027 0.80 SRC (0.80) SRCCA12CA1CA2CA9
SCHEMBL30150807 0.80 SRC (0.80) SRCCA12CA1CA2CA9
SCHEMBL30150810 0.80 SRC (0.80) SRCCA12CA1CA2CA9
SCHEMBL22086441 0.80 SRC (0.55) SRCCA12CA1CA2CA9
SCHEMBL22086539 0.80 SRC (0.64) SRCCA12CA1CA2CA9
SCHEMBL22086067 0.79 SRC (0.78) SRCCA12CA1CA2CA9
SCHEMBL22084757 0.76 SRC (0.55) SRCCA12CA1CA2CA9
SCHEMBL25066072 0.72 SRC (0.53) SRCLMNATP53HTTMEN1
SCHEMBL22084739 0.71 SRC (0.50) SRCCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055250-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-02-23 — — US disclosed
WO-2020115481-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) 2020-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055250-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K5, MAP4K1 SRC 739/4885CA12 4722/4885CA1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback